R&D News | pharmaphorum

News

CVS retreats from the clinical trial business

CVS Health has decided to shut down its clinical trials business, just two years after launching it to great fanfare in the midst of the COVID-19 pandemic.

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

AI project aims to strip racial bias from lung disease R&D

A new project has been launched to develop artificial intelligence models that more closely reflect the diversity seen in patients with lung disease in the UK.

News

GSK chases down Pfizer in 5-in-1 meningitis jab contest

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a chall

News

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

News

AI algorithm ‘could improve heart attack diagnosis’

Researchers in the UK have said that an algorithm developed using artificial intelligence could help doctors decide more quickly if a patient has suffered a heart attack,

CVS retreats from the clinical trial business

AstraZeneca builds in cancer ADCs again, with LaNova deal

AI project aims to strip racial bias from lung disease R&D

GSK chases down Pfizer in 5-in-1 meningitis jab contest

After FDA snub, DBV charts a new course for Viaskin peanut

AI algorithm ‘could improve heart attack diagnosis’

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks